Payment overview · 2025
General Payments
$18.24
1 reported records · 1 companies
Healthcare provider profile · identity verified
Simcha Weissman, DO
Allopathic & Osteopathic Physicians|Family Medicine · NORTH BERGEN, NJ · NPI 1457810798
Verified facts
What the public records show
CMS Open Payments records show Simcha Weissman, DO received $18.24 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.24 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.24 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 15 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 283 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | suppressed |
| Lisinopril | Lisinopril | 126 | 26 |
| Mirtazapine | Mirtazapine | 125 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | suppressed |
| Jardiance | Empagliflozin | 114 | 11 |
| Divalproex Sodium | Divalproex Sodium | 113 | suppressed |
| Furosemide | Furosemide | 104 | 22 |
| Eliquis | Apixaban | 97 | 12 |
| Losartan Potassium | Losartan Potassium | 94 | 19 |
| Metformin Hcl | Metformin Hcl | 92 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 75 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 17 |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Carvedilol | Carvedilol | 58 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 13 |
| Gabapentin | Gabapentin | 53 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 23 |
| Memantine Hcl | Memantine Hcl | 52 | 11 |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 12 |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 14 |
| Scopolamine | Scopolamine | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 13 |
| Atenolol | Atenolol | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 11 |
| Nuplazid | Pimavanserin Tartrate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 19 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.24 · 1 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error